The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseases are treated.
Candid Therapeutics is two years old. It does not have an approved drug. Its lead programme has been tested in roughly 100 patients across multiple early-stage trials. On Sunday, UCB, the Brussels-listed pharmaceutical company, agreed to buy it for up to $2.2bn.
That kind of price for that kind of biotech needs an explanation, and the explanation, in 2026, has a name: T-cell engagers in autoimmune disease.
Under the agreement announced on 3 May, UCB will pay $2bn in upfront cash, with up to $200m in additional milestone payments tied to development and regulatory progress.
The deal, is expected to close by the end of the second quarter or early in the third, subject to antitrust clearance. UCB has reaffirmed its 2026 financial guidance, which suggests it intends to absorb the transaction without recutting expectations.
It is the second time in a matter of months that the Belgian company has reached for the same therapeutic mechanism. In an earlier transaction, UCB licensed ATG-201, a CD19/CD3 bispecific from China-based Antengene, in a deal worth up to $1.1bn. The Candid acquisition lands on top of that and adds a different B-cell target.
What Candid actually has?
Candid’s lead asset is cizutamig, a bispecific antibody designed to bridge two cells: it grabs a T-cell on one end via CD3 and a plasma cell on the other via BCMA, the B-cell maturation antigen, instructing the T-cell to destroy the plasma cell.
The mechanism was developed for multiple myeloma, where killing rogue plasma cells is the entire point of treatment. The 2026 thesis is that the same engine can be repurposed to deplete the autoreactive B-cells and plasma cells driving autoimmune diseases such as lupus, myasthenia gravis, and a long list of less famous conditions in which the immune system attacks its own tissues.
According to UCB, cizutamig has now been clinically evaluated in over 100 patients combined across multiple myeloma and autoimmune indications, and is currently in Phase 1 studies across more than ten autoimmune diseases.
UCB describes it, in its statement, as a potential best-in-class BCMA T-cell engager for autoimmune disease, language that is both ambitious and conventional for press releases of this kind.
The reason buyers are willing to write nine-figure cheques on Phase 1 data is that the early autoimmune signals from this drug class, broadly, have been genuinely striking. Patients with severe disease have shown durable remissions after a single course of B-cell-depleting therapy, including in conditions where decades of small-molecule and biologic treatment have produced only partial control. None of this is yet definitive.
Late-stage data, larger cohorts, and longer follow-up will all be required. But the direction has been consistent enough that pharma boardrooms have begun pricing the modality as if it works.
Candid was founded in 2024 in San Diego, with backing from Two River Group and Vida Ventures and a launch financing of $370m. Its chairman, chief executive and president is Dr Ken Song, who previously led RayzeBio through its $4.1bn acquisition by Bristol Myers Squibb in late 2023. Building, scaling, and selling clinical-stage oncology and immunology biotechs is, in other words, what he does.
That history is part of what UCB is paying for. Buyers in this segment of the market are increasingly willing to underwrite management quality alongside molecule quality, particularly when the molecule’s commercial promise depends on disciplined trial design across a large number of small indications.
The valuation gap between the original $370m launch funding in mid-2024 and the $2bn upfront UCB is paying now, in cash, less than two years later, is a fair indicator of what investors think he and his team have built.
It is also a sharp reversal. In March, Candid had announced a reverse merger with Rallybio, a publicly listed but smaller rare-disease company, intended to take Candid public via a back-door listing. That transaction, by all appearances, has now been superseded. UCB’s offer was, presumably, the better one.
UCB’s purchase fits into a pattern that has become hard to miss. Over the past nine months, every major pharma company with an immunology presence has either bought, licensed, or partnered around T-cell engagers aimed at autoimmune disease.
Gilead acquired Ouro Medicines for $2.18bn earlier this year, picking up gamgertamig, another BCMAxCD3 engager. Sanofi licensed a trispecific from Kali Therapeutics in a deal worth up to $1.2bn. GSK paid $300m to license a CMG1A46 candidate from Chimagen for lupus. Prolium Bioscience launched in March with $50m to develop a CD20xCD3 engager. The list lengthens almost weekly.
Two facts explain the rush. The first is that the science, finally, looks like it might generalise; what worked in oncology to remove malignant B-cells appears to work in autoimmune disease to remove autoreactive ones, and the early human data are far better than the conventional pharmacology playbook predicted.
The second is that immunology is, by some distance, the largest pharmaceutical market in the world after oncology. Drugs like AbbVie’s Humira, before its biosimilar erosion, and Sanofi’s Dupixent are reminders that successful autoimmune therapies generate revenue at a scale to which only a handful of categories aspire.
If TCEs work in this setting, the prize is correspondingly large. If they do not, several of these deals will look expensive in retrospect.
Where the AI conversation does not quite fit
It is worth noting what is not driving the deal. Despite the surge of attention to AI-discovered medicines, from Google DeepMind spinoff Isomorphic Labs entering trials this year to ByteDance’s Anew Labs presenting its first AI-designed therapy and Anthropic paying $400m for a 10-person biotech startup to design protein-based drugs, cizutamig itself is a conventionally designed biologic.
It was discovered through licensing relationships and standard antibody engineering, not generative protein models. The molecules driving today’s autoimmune deal flow are, almost without exception, products of a previous decade’s chemistry.
AI’s promised acceleration in drug discovery has, so far, produced more announcements than approvals.
The Candid deal is, in that sense, a reminder that pharma’s largest near-term value creation is happening in molecules that were already in the pipeline before the AI hype cycle began. The next set of acquisitions, in two or three years, may well include AI-discovered candidates. This one does not need to.
What UCB now has, and what it has to prove
For UCB, the strategic logic is clean. The company is mid-sized in pharma terms, with a long-standing immunology franchise and a recent track record of opening up new therapeutic areas through targeted M&A.
Pairing the Antengene CD19xCD3 candidate with Candid’s BCMAxCD3 lead asset gives it two complementary B-cell-depleting mechanisms in a market that increasingly looks as though it will reward platform breadth rather than single-molecule excellence.
What UCB has to prove is execution. Phase 1 data in autoimmune disease are encouraging but thin. The competitive density is unusually high, with at least half a dozen large pharma companies pursuing similar mechanisms across overlapping indications. Pricing pressure, both regulatory and from payers, will hit any successful TCE the moment it nears approval. And manufacturing bispecific antibodies at scale is non-trivial. None of these is fatal. All of them are real.
By the time the deal closes this summer, the broader market may have adjusted its enthusiasm for the modality up or down. UCB has chosen to act before that adjustment.
Whether that proves to be timely or expensive will be visible in the Phase 2 readouts due over the next 18 months. For now, a two-year-old company that started as an autoimmune-disease bet by an experienced operator has been priced at $2.2bn, in cash, by a pharma company convinced that the bet is correct.
You must be logged in to post a comment Login